ADHD | nuaxia

top of page

The Professional Network for Healthcare Experts

Clients
Healthcare Professionals
Alerts
Testimonials
More...

Use tab to navigate through the menu items.

Express Interest

All Posts
Compensation
Deals
Industry Updates
Approvals
nuaxia Insights

Search

FDA approves Simtriyo for ADHD in adults and children aged 6 years and older

FDA approves Simtriyo for ADHD in adults and children aged 6 years and older

FDA approves Simtriyo for ADHD in adults and children aged 6 years and older

The once-daily treatment introduces the first approved norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD, with US availability dependent on DEA scheduling.

nuaxia

3 days ago2 min read

Terms
Privacy Notice
Cookie Notice
The nuaxia Team
Corporate Information
More...

Use tab to navigate through the menu items.

© nuaxia Limited 2016-2026

by Tarryn Jordaan

bottom of page